The Athos laser is intended for hair removal (destruction of hair follicles) in all skin types and for soft tissue applications. The soft tissue applications are for the coagulation, photocoagulation, incision/excision, ablation, and vaporization of soft tissues including skin, cutaneous tissue, subcutaneous tissue, striated and smooth tissue, muscle, cartilage meniscus, mucous membrane, lymph vessels and nodes, organs and glands.

Dermatology: In addition to the tissue types cited, pigmented lesions to reduce lesion size; for patients with lesions that would potentially benefit from aggressive treatment; for patients with lesions that have not responded to other laser treatments.

Endoscopic/Laparoscopic General Surgery: Incision/excision and cutting, ablation, coagulation/hemostasis of soft tissue in endoscopic, laparoscopic surgery applications, including but not limited to cholecystectomy, appendectomy, vagotomy, and pyloromyotomy.

Tissue ablation and hemostasis in the GI tract; Gastroenterology: esophageal neoplastic obstructions including squamous cell carcinoma and adenocarcinoma; GI hemostasis; including varices, esophagitis, esophageal ulcer, Mallory-Weiss tear, gastric ulcer, angiodysplasia, stomal ulcers, nonbleeding ulcers gastric erosions GI tissue ablation including benign and malignant neoplasms, angiodysplasia; polyps, ulcer, colitis, and hemorrhoids.

General Surgery: Soft tissue in general surgery applications, skin incisions, tissue dissection, excision of external tumors and lesions, complete or partial resection of internal organs, tumors, lesions, tissue ablation, vessel coagulation.

Treatment of menorrhagia by photocoagulation of thee Gynecology: endometrial lining of the uterus, ablation of endometrial implants and/or peritoneal adhesions, soft tissue excision procedures such as conization of the cervix, intra-uterine gynecologic procedures where cutting, ablation and/or vessel coagulation may be indicated including submucous fibroids, benign endometrial polyps, uterine septum.

Head and Neck/Otorhinolaryngology (ENT): For the coagulation, photocoagulation, incision/excision, ablation, and vaporization of soft tissue.

Hemostasis during surgery: Adjunctive coagulation and hemostasis (control of bleeding) during surgery (endoscopic, laparoscopic, and open procedures).

Neurosurgery: Hemostasis of pituitary tumor, meningioma, hemagioblastoma, AVMs, glioma, glioblastoma, astrocytoma, oligodendroglioma.

Oculoplastics: Incision, excision, vaporization, ablation, and coagulation of soft tissues in oculoplastic procedures such as operations on the lacrimal system, operation on the eyelids, removal of biopsy or orbital turnors, enucleation of the eyeball, exteneration of orbital contents.

Orthopedics: Incision, excision, cutting, ablation and/or hemostasis of intraarticular tissue in orthopedic surgical and arthroscopic applications.

Plastic Surgery: Incision, excision, cutting, coagulation, and vaporization soft tissue.

Pulmonary/Thoracic Surgery: Palliative treatment of benign and malignant pulmonary airway obstructions including squamous cell carcinoma, adenocarcinoma, carcinoid, benign tumors, granulomas, and benign strictures.

Thoracic Surgery: Incision, excision, cutting, coagulation, and vaporization of soft tissue, including lung tissue, in thoracic applications including but not limited to isolation of vessels for endarterectomy and/or by-pass grafts, wedge resections, thoractomy, formation of pacemaker pockets.

Urology: All applications including superficial urinary bladder turnors, invasive bladder carcinoma, urethral strictures, and lesions of the external genitalia (including condyloma accuminata).

Device Description

The Athos laser emits a beam of coherent light at 1064 microns.

AI/ML Overview

The provided document is a 510(k) summary for the Athos Long Pulsed Nd:YAG laser. This type of submission focuses on demonstrating substantial equivalence to a predicate device rather than providing extensive performance data from clinical trials.

Therefore, the document explicitly states: "Performance Data: None required."

This means that a formal study proving the device meets acceptance criteria, complete with detailed performance metrics, sample sizes, expert involvement, and ground truth establishment, was not conducted or required for this particular 510(k) clearance. The clearance was based on demonstrating equivalence to an already legally marketed device (K001704).

Given this, I cannot provide the requested information. The sections below are included for completeness, but they reflect the absence of such data in the provided text.

1. Table of Acceptance Criteria and Reported Device Performance:

Acceptance Criteria	Reported Device Performance
Not specified/not required for 510(k) submission.	Not applicable/not reported.

2. Sample size used for the test set and the data provenance:

Test Set Sample Size: Not applicable; no performance study reported.
Data Provenance: Not applicable; no performance study reported.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

Number of Experts: Not applicable; no performance study reported.
Qualifications of Experts: Not applicable; no performance study reported.

4. Adjudication method for the test set:

Adjudication Method: Not applicable; no performance study reported.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance:

MRMC Study: No, this is not an AI-assisted device, and no such comparative effectiveness study was reported.
Effect Size: Not applicable.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

Standalone Performance: Not applicable; this is a laser device, not an algorithm.

7. The type of ground truth used:

Type of Ground Truth: Not applicable; no performance study reported.

8. The sample size for the training set:

Training Set Sample Size: Not applicable; no performance study involving a training set was reported.

9. How the ground truth for the training set was established:

Ground Truth for Training Set Establishment: Not applicable; no performance study involving a training set was reported.

Summary

{0}------------------------------------------------

SECTION 10 510(k) SUMMARY

K020072 113

This 510(k) summary of safety and effectiveness for the Athos Long Pulsed Nd:YAG laser is submitted in accordance with the requirements of SMDA 1990 and follows Office of Device Evaluation guidance concerning the organization and content of a 510(k) summary.

Quantel Medical Applicant:

QUANTEL MEDICAL Address: 21 rue Newton ZI du BREZET 63039 Clermont-Ferrand Cedex 2 FRANCE +33 (0)473 745 745 +33 (0)473 745 700 (Fax)

Mr. Jean Abascal Contact Person:

(+33) 169 29 17 25 (+33) 169 29 17 29

Preparation Date: December 2001 (of the Summary)

Athos laser Device Name:

Nd: YAG Surgical Laser (Long Pulse Nd: YAG laser) Common Name:

Laser surgical instrument for use in general and plastic surgery and in Classification dermatology (see: 21 CFR 878.4810). Name: Product Code: GEX Panel: 79 :

The Athos Long Pulse Nd:YAG laser Predicate device:

Device description: The Athos laser emits a beam of coherent light at 1064 microns.

The Athos laser is intended for hair removal (destruction of hair follicles) in Indications: all skin types and for soft tissue applications.

{1}------------------------------------------------

The soft tissue applications are for the coagulation, photocoagulation, incision/excision, ablation, and vaporization of soft tissues including skin, cutaneous tissue, subcutaneous tissue, striated and smooth tissue, muscle, cartilage meniscus, mucous membrane, lymph vessels and nodes, organs and glands.

Head and Neck/Otorhinolaryngology (ENT): For the coagulation, photocoagulation, incision/excision, ablation, and vaporization of soft tissue.

Hemostasis during surgery: Adjunctive coagulation and hemostasis (control of bleeding) during surgery (endoscopic, laparoscopic, and open procedures).

Neurosurgery: Hemostasis of pituitary tumor, meningioma, hemagioblastoma, AVMs, glioma, glioblastoma, astrocytoma, oligodendroglioma.

2/3

K020072

{2}------------------------------------------------

K020072 3/3

Orthopedics: Incision, excision, cutting, ablation and/or hemostasis of intraarticular tissue in orthopedic surgical and arthroscopic applications.

Plastic Surgery: Incision, excision, cutting, coagulation, and vaporization soft tissue.

Urology: All applications including superficial urinary bladder turnors, invasive bladder carcinoma, urethral strictures, and lesions of the external genitalia (including condyloma accuminata).

The Athos laser will be labeled as a prescription device:

CAUTION: Federal (US) law restricts the use of this device to licensed professionals.

Performance Data: None required.

CONCLUSION:

Based on the information in the notification Quantel Medical concludes that the Athos laser which is the subject of this notification is substantially equivalent to the Athos laser described in K001704 under the conditions of intended use.

{3}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle or bird design, composed of three overlapping profiles facing to the right. The profiles are black, and the overall design is simple and modern. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the bird symbol.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR - 9 2002

Quantel Medical c/o Mr. Roger W. Barnes 342 Sunset Bay Road Hot Springs, AR 71913

Re: K020072

Trade/Device Name: Athos Laser Regulation Number: 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: January 7, 2002 Received: January 9, 2002

Dear Mr. Barnes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

Page 2 -- Mr. Roger W. Barnes

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Muriam C. Provost

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

SECTION 7

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K020072

Device Name: Athos laser (Nd: YAG Long-pulsed laser)

Indications for Use Statement:

The Athos laser is intended for hair removal (destruction of hair follicles) in all skin types and for soft tissue applications.

Dermatology: In addition to the tissue types cited, pigmented lesions to reduce lesion size: for patients with lesions that would potentially benefit from aggressive treatment; for patients with lesions that have not responded to other laser treatments.

Endoscopic/Laparoscopic General Surgery: Incision and cutting, ablation, coagulation/hemostasis of soft tissue in endoscopic, laparoscopic surgery applications, including but not limited to cholecystectomy, appendectomy, vagotomy, and pyloromyotomy.

Tissue ablation and hemostasis in the GI tract; esophageal Gastroenterology: neoplastic obstructions including squamous cell carcinoma and adenocarcinoma; GI hemostasis; including varices, esophagitis, esophageal ulcer, Mallory-Weiss tear, gastric ulcer, angiodysplasia, stomal ulcers, non-bleeding ulcers gastric erosions GI tissue ablation including benign and malignant neoplasms, angiodysplasia; polyps, ulcer, colitis, and hemorrhoids.

Continued on second page

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation

Prescription Use 17 (Per 21 CFR 801.109) OR

Over-The Counter Use

Indications for Use Statement: (Continued)

{6}------------------------------------------------

K020072 2/3

Gynecology: Treatment of menorrhagia by photocoagulation of thee endometrial lining of the uterus, ablation of endometrial implants and/or peritoneal adhesions, soft tissue excision procedures such as conization of the cervix, intra-uterine gynecologic procedures where cutting, ablation and/or vessel coagulation may be indicated including submucous fibroids, benign endometrial polyps, uterine septum.

Head and Neck/Otorhinolaryngology (ENT): Coagulation, photocoagulation, incision/excision, ablation, and vaporization of soft tissue.

Hemostasis during surgery: Adjunctive coagulation and hemostasis (control of bleeding)

during surgery (endoscopic, laparoscopic, and open procedures).

Hemostasis of pituitary tumor, meningioma, hemagioblastoma, Neurosurgery: AVMs. glioma, glioblastoma, astrocytoma, oligodendroglioma.

Incision, excision, vaporization, ablation, and coagulation of soft Oculoplastics: tissues in oculoplastic procedures such as operations on the lacrimal system, operation on the eyelids. removal of biopsy or orbital tumors, enucleation of the eyeball, exteneration of orbital contents.

Orthopedics: Incision, excision, cutting, ablation and/or hemostasis of intra-articular tissue in orthopedic surgical and arthroscopic applications.

Plastic Surgery: Incision, excision, cutting, coagulation, and vaporization soft tissue.

Palliative treatment of benign and malignant Pulmonary/Thoracic Surgery: pulmonary airway obstructions including squamous cell carcinoma, adenocarcinoma, carcinoid, benign tumors, granulomas, and benign strictures.

Urology: All applications including superficial urinary bladder tumors, invasive bladder carcinoma, urethral strictures, and lesions of the external genitalia (including condyloma accuminata).

The Athos laser will be labeled as a prescription device as follows:

{7}------------------------------------------------

K0200723/3

CAUTION: Federal (US) law restricts the use of this device to licensed.professionals

・

Miriam C. Provost

(Division Sign-Off) Division of General, Restorative and Neurological Devices

510(k) Number_________________________________________________________________________________________________________________________________________________________________

Regulation Number and Section

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.